OTCQB
BVAXF

Biovaxys Technology Corp

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Biovaxys Technology Corp Stock Price

Vitals

Today's Low:
$0.0145
Today's High:
$0.0164
Open Price:
$0.015
52W Low:
$0.018
52W High:
$0.195
Prev. Close:
$0.0143
Volume:
44982

Company Statistics

Market Cap.:
$3.48 million
Book Value:
-0.005
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-45.77%
Return on Equity TTM:
-350.17%

Company Profile

Biovaxys Technology Corp had its IPO on under the ticker symbol BVAXF.

The company operates in the Healthcare sector and Biotechnology industry. Biovaxys Technology Corp has a staff strength of 0 employees.

Stock update

Shares of Biovaxys Technology Corp opened at $0.02 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.01 - $0.02, and closed at $0.01.

This is a +1.4% increase from the previous day's closing price.

A total volume of 44,982 shares were traded at the close of the day’s session.

In the last one week, shares of Biovaxys Technology Corp have slipped by -30.62%.

Biovaxys Technology Corp's Key Ratios

Biovaxys Technology Corp has a market cap of $3.48 million, indicating a price to book ratio of 2.5319 and a price to sales ratio of 0.

In the last 12-months Biovaxys Technology Corp’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Biovaxys Technology Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Biovaxys Technology Corp’s operating margin was 0% while its return on assets stood at -45.77% with a return of equity of -350.17%.

In Q0.33333333333333, Biovaxys Technology Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Biovaxys Technology Corp’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.1 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Biovaxys Technology Corp’s profitability.

Biovaxys Technology Corp stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.0007. Its price to sales ratio in the trailing 12-months stood at 0.

Biovaxys Technology Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$1.26 million
Total Liabilities
$1.88 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Biovaxys Technology Corp ended 2024 with $1.26 million in total assets and $0 in total liabilities. Its intangible assets were valued at $1.26 million while shareholder equity stood at $-616726.00.

Biovaxys Technology Corp ended 2024 with $0 in deferred long-term liabilities, $1.88 million in other current liabilities, in common stock, $-20564331.00 in retained earnings and $0 in goodwill. Its cash balance stood at $71613.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.

Biovaxys Technology Corp’s total current assets stands at $1.11 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.42 million and inventory worth $0.

In 2024, Biovaxys Technology Corp's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Biovaxys Technology Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.01
52-Week High
$0.195
52-Week Low
$0.018
Analyst Target Price
$

Biovaxys Technology Corp stock is currently trading at $0.01 per share. It touched a 52-week high of $0.195 and a 52-week low of $0.195. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.02 and 200-day moving average was $0.05 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 1894.5% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Biovaxys Technology Corp

The stock symbol (also called stock or share ticker) of Biovaxys Technology Corp is BVAXF

The IPO of Biovaxys Technology Corp took place on

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$63.96
0.31
+0.49%
$14.7
0
0%
$14.9
-0.1
-0.67%
$1.41
0.06
+4.44%
$50.09
2.33
+4.88%
KDDL LTD.-$ (KDDL)
$1808
-66.1
-3.53%
$45
-2.31
-4.88%
$137.78
0.07
+0.05%
$3523
-168.8
-4.57%
$1387.9
-73.05
-5%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

BioVaxys Technology Corp., a clinical-stage immunotherapeutic company, engages in developing antiviral and anticancer vaccine platforms. It develops BVX-0320, a SARS-CoV-2 vaccine; BVX-1021, a vaccine for the strain of coronavirus that causes SARS1; and BVX-0918, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, a novel diagnostic platform to identify a T-cell immune response to the presence of SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions. It has a bioproduction agreement with WuXi Biologics Limited to produce SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; and research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320. BioVaxys Technology Corp. is based in Vancouver, Canada.

Address

905 West Pender Street, Vancouver, BC, Canada, V6C 1L6